French prospective observational study of patients receiving dupilumab for atopic dermatitis
Topic / Pathology
- observational
- Paediatric
- Biologic
Objectives
Long-term study to collect data over a three-year period to determine what is likely to happen in the future in participants aged 6 years and older who receive dupilumab for atopic dermatitis (AD), and to characterize the efficacy, safety and patterns of use of dupilumab in the real world.All patients over 6 years of age will be invited to participate in the study if they initiate treatment with dupilumab for AD in accordance with actual prescribing practice information specific to France.
Sponsor
Sanofi
Investigator
Dr Anne-Claire Fougerousse
Critères d'inclusion
- Initiate dupilumab treatment for AD according to prescribing information specific to France (≥ 12 years: moderate to severe AD versus 6-11 years: severe AD). The decision to initiate treatment is independent of study participation.
- Ability to understand and complete study questionnaires.
Critères de non-inclusion
- Patients who have a contraindication to the drug according to the label in the prescribing information specific to France.
- Any condition that, in the opinion of the investigator, may interfere with the patient's ability to participate in the study, such as reduced life expectancy, substance abuse, severe cognitive impairment or other comorbidities that may prevent the patient from properly completing, according to usual care, the schedule of visits and assessments.
- Patients currently participating in an interventional clinical trial.
- Patients previously treated with dupilumab.
Status
Ongoing
